|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
LabCentral,Cambridge,Massachusetts,US
|
|
Carmine Therapeutics, headquartered in Cambridge MA, is pioneering a new class of non-viral gene therapies based on red blood cell extracellular vesicles, combined with proprietary payloads. In June 2020, Carmine inked a research alliance with Takeda Pharmaceuticals worth up to $900 million to develop non-viral gene therapies for 2 targets. Carmine has also been named one of the FierceBiotech’s Fierce 15 Biotech companies of 2020 and was also awarded the Bristol-Myers Squibb "Golden Ticket". Carmine was founded in 2019 by Esco Ventures X, Professors Harvey Lodish (Whitehead, MIT), Minh Le and Jiahai Shi. Professor Lodish, who was a founding member of several successful biotech companies that include Genzyme and Millennium Pharmaceuticals, is also Chair of the Scientific Advisory Board of Carmine.
For more information, visit www.carminetherapeutics.com
Media Relations
[email protected]
Investor Relations
[email protected]
|
Carmine Therapeutics Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Carmine Therapeutics email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Carmine Therapeutics customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.